Skip to search formSkip to main contentSkip to account menu

naptumomab estafenatox

A recombinant fusion protein consisting of the antigen-binding fragment of a monoclonal antibody directed towards the tumor-associated oncofetal… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Purpose: To prospectively determine the efficacy of naptumomab estafenatox (Nap) + IFNα versus IFN in metastatic renal cell… 
2015
2015
Naptumomab estafenatox/ABR-217620/ANYARA (Nap) has been evaluated in clinical phase 1 and 2/3 studies. RCC patients in the phase… 
Review
2014
Review
2014
Improvement of cancer therapy by introducing new concepts is still urgent even though there have been major advancements lately… 
Review
2013
Review
2013
The start of the new year signals that it is time for mAbs’ annual review of the therapeutic monoclonal antibodies (mAbs) in… 
Review
2013
Review
2013
The transitions of antibody therapeutics to late-stage clinical development, regulatory review and the market are proceeding at a… 
Review
2011
Review
2011
This overview of 25 monoclonal antibody (mAb) and 5 Fc fusion protein therapeutics provides brief descriptions of the candidates… 
2010
2010
Antibody-targeted superantigens have a potential to become useful drugs for tumor therapy. However, clinical practice has… 
Review
2010
Review
2010
Importance of the field: New agents that specifically engage the immune system are being tested in a variety of malignancies… 
Highly Cited
2010
Highly Cited
2010
Traditionally, the major objective in phase I trials is to identify a working-dose for subsequent studies, whereas the major… 
Highly Cited
2009
Highly Cited
2009
PURPOSE Two phase I studies were conducted of ABR-217620 alone or in combination with docetaxel. This is a recombinant fusion…